tiprankstipranks
Trending News
More News >
JB Chemicals & Pharmaceuticals Ltd. (IN:JBCHEPHARM)
:JBCHEPHARM
India Market
Advertisement

JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) Price & Analysis

Compare
3 Followers

JBCHEPHARM Stock Chart & Stats


JB Chemicals & Pharmaceuticals Ltd. News

JBCHEPHARM FAQ

What was JB Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
JB Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹1303.00 and its highest was ₹1998.00 in the past 12 months.
    What is JB Chemicals & Pharmaceuticals Ltd.’s market cap?
    JB Chemicals & Pharmaceuticals Ltd.’s market cap is ₹262.55B.
      When is JB Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
      JB Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 06, 2025 which is in 27 days.
        How were JB Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
        JB Chemicals & Pharmaceuticals Ltd. released its earnings results on Jul 30, 2025. The company reported ₹13.7 earnings per share for the quarter, beating the consensus estimate of ₹13.6 by ₹0.1.
          Is JB Chemicals & Pharmaceuticals Ltd. overvalued?
          According to Wall Street analysts JB Chemicals & Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does JB Chemicals & Pharmaceuticals Ltd. pay dividends?
            JB Chemicals & Pharmaceuticals Ltd. pays a Semiannually dividend of ₹7 which represents an annual dividend yield of 0.92%. See more information on JB Chemicals & Pharmaceuticals Ltd. dividends here
              What is JB Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
              JB Chemicals & Pharmaceuticals Ltd.’s EPS estimate is 12.9.
                How many shares outstanding does JB Chemicals & Pharmaceuticals Ltd. have?
                JB Chemicals & Pharmaceuticals Ltd. has 156,596,240 shares outstanding.
                  What happened to JB Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
                  JB Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹13.7 in its last earnings report, beating expectations of ₹13.6. Following the earnings report the stock price went down -0.699%.
                    Which hedge fund is a major shareholder of JB Chemicals & Pharmaceuticals Ltd.?
                    Currently, no hedge funds are holding shares in IN:JBCHEPHARM

                    Company Description

                    JB Chemicals & Pharmaceuticals Ltd.

                    J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. Its principal products include Cilnidipine, Ranitidine, and Metronidazole. The company also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners. Further, the company provides its services in gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is based in Mumbai, India.

                    JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) Earnings & Revenues

                    JBCHEPHARM Stock 12 Month Forecast

                    Average Price Target

                    ₹1,824.00
                    ▲(9.09% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1543":"₹1,543","1940":"₹1,940","1642.25":"₹1,642.3","1741.5":"₹1,741.5","1840.75":"₹1,840.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.82K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.82K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.82K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1543,1642.25,1741.5,1840.75,1940],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1688.95,1699.3384615384616,1709.7269230769232,1720.1153846153848,1730.503846153846,1740.8923076923077,1751.2807692307692,1761.6692307692308,1772.0576923076924,1782.446153846154,1792.8346153846153,1803.2230769230769,1813.6115384615384,{"y":1824,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1688.95,1699.3384615384616,1709.7269230769232,1720.1153846153848,1730.503846153846,1740.8923076923077,1751.2807692307692,1761.6692307692308,1772.0576923076924,1782.446153846154,1792.8346153846153,1803.2230769230769,1813.6115384615384,{"y":1824,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1688.95,1699.3384615384616,1709.7269230769232,1720.1153846153848,1730.503846153846,1740.8923076923077,1751.2807692307692,1761.6692307692308,1772.0576923076924,1782.446153846154,1792.8346153846153,1803.2230769230769,1813.6115384615384,{"y":1824,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1939.51,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1741.96,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1861.2,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1743.95,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1639.71,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1544.08,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1604,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1682.09,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1640.26,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1640.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1735.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1724.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1688.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Ajanta Pharma Limited
                    Emcure Pharmaceuticals Limited
                    Gland Pharma Ltd.
                    Glenmark Pharmaceuticals Limited
                    PFIZER LIMITED
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis